{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:03:37Z","timestamp":1788498217964,"version":"build-2803163510"},"reference-count":34,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>After seven decades of levothyroxine (LT4) replacement therapy, dosage adjustment still takes several months. We have developed a decision aid tool (DAT) that models LT4 pharmacometrics and enables patient-tailored dosage. The aim of this was to speed up dosage adjustments for patients after total thyroidectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The DAT computer program was developed with a group of 46 patients post-thyroidectomy, and it was then applied in a prospective randomized multicenter validation trial in 145 unselected patients admitted for total thyroidectomy for goiter, differentiated thyroid cancer, or thyrotoxicosis. The LT4 dosage was adjusted after only two weeks, with or without application of the DAT, which calculated individual free thyroxine (fT4) targets based on four repeated measurements of fT4 and thyrotropin (TSH) levels. The individual TSH target was either &lt;0.1, 0.1\u20130.5, or 0.5\u20132.0 mIU\/L, depending on the diagnosis. Initial postoperative LT4 dosage was determined according to clinical routine without using algorithms. A simplified DAT with a population-based fT4 target was used for thyrotoxic patients who often went into surgery after prolonged TSH suppression. Subsequent LT4 adjustments were carried out every six weeks until target TSH was achieved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>When clinicians were guided by the DAT, 40% of patients with goiter and 59% of patients with cancer satisfied the narrow TSH targets eight weeks after surgery, as compared with only 0% and 19% of the controls, respectively. The TSH was within the normal range in 80% of DAT\/goiter patients eight weeks after surgery as compared with 19% of controls. The DAT shortened the average dosage adjustment period by 58 days in the goiter group and 40 days in the cancer group. For thyrotoxic patients, application of the simplified DAT did not improve the dosage adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Application of the DAT in combination with early postoperative TSH and fT4 monitoring offers a fast approach to LT4 dosage after total thyroidectomy for patients with goiter or differentiated thyroid cancer. Estimation of individual TSH-fT4 dynamics was crucial for the model to work, as removal of this feature in the applied model for thyrotoxic patients also removed the benefit of the DAT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2021.0125","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T01:21:21Z","timestamp":1620868881000},"page":"1297-1304","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Patient-Tailored Levothyroxine Dosage with Pharmacokinetic\/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4136-3073","authenticated-orcid":false,"given":"Vegard Heimly","family":"Brun","sequence":"first","affiliation":[{"name":"Department of Breast and Endocrine Surgery, University Hospital of North Norway, Troms\u00f8, Norway."},{"name":"Institute of Clinical Medicine, University in Troms\u00f8\u2014The Arctic University of Norway, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amund H.","family":"Eriksen","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, University Hospital of North Norway, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Selseth","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, University Hospital of North Norway, Troms\u00f8, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenth","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Surgery, V\u00e4stervik Hospital, V\u00e4stervik, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Vik","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Haukeland University Hospital, Bergen, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Davidsen","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Haukeland University Hospital, Bergen, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kaut","sequence":"additional","affiliation":[{"name":"Department of Sustainable Energy Technology, SINTEF Industry, Trondheim, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hellemo","sequence":"additional","affiliation":[{"name":"Department of Sustainable Energy Technology, SINTEF Industry, Trondheim, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.04.097"},{"key":"e_1_3_6_3_2","unstructured":"Health Norwegian Institue of Public Health. 2019. The Norwegian Prescription Database 2014\u20132018. Oslo Norway."},{"key":"e_1_3_6_4_2","unstructured":"Free U.S. Outpatient Drug Usage Statistics. Available at https:\/\/clincalc.com\/DrugStats ClinCalc DrugStats Database (Accessed June7 2021)."},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02006-8"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.5157"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2012.12.002"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-7-200104030-00009"},{"key":"e_1_3_6_9_2","first-page":"334","article-title":"Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine","volume":"77","author":"Biondi B","year":"1993","unstructured":"Biondi B, , Fazio S, , Carella C, , Amato G, , Cittadini A, , Lupoli G, , Sacca L, , Bellastella A, , Lombardi G. 1993. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab, 77:334\u2013338.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311901"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-013-9886-1"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02051-3"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0727"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0517"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0672"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-1229"},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","unstructured":"Thvilum M Brandt F Lillevang-Johansen M Folkestad L Brix TH Hegedus L 2021 Increased risk of dementia in hypothyroidism: a Danish nationwide register-based study. Clin Endocrinol (Oxf).","DOI":"10.1111\/cen.14424"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4468"},{"key":"e_1_3_6_19_2","first-page":"4925","article-title":"The impact of thyroid diseases on the working life of patients: a systematic review","volume":"17","author":"Leso V","year":"2020","unstructured":"Leso V, , Vetrani I, , De Cicco L, , Cardelia A, , Fontana L, , Buonocore G, , Iavicoli I. 2020. The impact of thyroid diseases on the working life of patients: a systematic review. Int J Environ Res Public Health, 17:4925.","journal-title":"Int J Environ Res Public Health"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2015.10.005"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0111"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03940.x"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0251"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.626268"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-2-453"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1990.10476213"},{"key":"e_1_3_6_27_2","unstructured":"Plummer M 2003 JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Vienna Austria Proceedings of the 3rd International Workshop on Distributed Statistical Computing 124."},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1137\/15M1020575"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1718"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2208"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0087"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060817"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703263161302"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-27-2-251"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408368409165776"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2021.0125","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2021.0125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2021.0125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:08:20Z","timestamp":1777586900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2021.0125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1089\/thy.2021.0125"],"URL":"https:\/\/doi.org\/10.1089\/thy.2021.0125","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}